Stem cell transplant: How skin-derived T cells can damage other organs
More than 40,000 allogeneic hematopoietic stem cell transplants are carried out worldwide every year, mostly for patients suffering from leukemia or other diseases of the hematopoietic system. Very often, the so-called graft-versus-host reaction occurs, an inflammatory disease that can affect different organs and is caused by an unwanted defense reaction of the donor cells and the body’s own T cells. Scientists at CeMM, Medical University of Vienna and LBI-RUD, led by Georg Stary, now show how these endogenous, tissue-derived T cells enter other organs, such as the intestine, via the blood and contribute to inflammation there. The study provides important approaches to better therapy in stem cell transplantation and new diagnostic options. It was published in the Journal of Experimental Medicine.
(Vienna, October 14, 2021) Stem cell transplants are an important, essential treatment method, especially for leukemia patients. According to the Transplant Annual Report 2020, 630 of these transplants were performed in Austria alone in 2019. In this process, all blood cells of the affected patient are first killed by chemotherapy and radiation, and then replaced by healthy bone marrow or blood stem cells from a donor. About half of the patients develop inflammatory skin diseases with serious consequences after the transplantation. T-cell-mediated rejection is one of the main causes of death after hematopoietic stem cell transplantation. In a previous study, a team of researchers led by dermatologist Georg Stary at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna and the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases was able to identify a mechanism that triggers this graft-versus-host reaction (graft-versus-host disease, GVHD). In skin samples taken from patients before and after transplantation, Stary and study author Johanna Strobl (MedUni) were able to show that host-derived T cells in the skin tissue are responsible for the inflammatory reactions.
Tissue-resident T cells of the skin migrate into the blood
In their current study, using the new model, Strobl and co-author Laura Marie Gail (CeMM/LBI-RUD) show that these tissue-resident T cells of the skin can be found in the blood of stem cell transplant patients. “The migration of the inflammatory, tissue-derived skin T cells into the bloodstream poses a risk of the skin inflammation being passed on to other organs. Especially in the intestine, which is often affected by GVHD, we found an astonishing number of cells that originally came from the skin,” say the study authors.
Deactivation of T cells as possible approach to improving therapy
For their study, Strobl, Gail and Stary investigated circulating T cells in the blood using samples from stem cell transplant patients. Using a special tracking method, the scientists were able to distinguish exactly which T cells were from the donor and which were from the patient. Research group leader Stary explains: “After all blood cells had already been killed by chemotherapy, we were able to conclude that the detected T cells could only come from the tissue. With the help of various markers, they could be traced back to the skin.”
Blood sample instead of biopsy
The study also provides indications for an additional important diagnostic aspect. The study authors were able to observe that more circulating T cells in stem cell transplant patients are detectable in the blood, depending on the clinical picture. Accordingly, it is quite conceivable that in the case of skin or tissue diseases, a blood analysis could be carried out and the phenotype of the skin-derived T cells in the blood evaluated instead of the time-consuming and often unpleasant sampling of the affected area. “This procedure would be a kind of ‘liquid biopsy’ in the case of inflammatory reactions in the tissue,” say the study authors.
The study ”Human resident memory T cells exit the skin and mediate systemic Th2-driven
inflammation“ was published in Journal of Experimental Medicine on 13 October 2021. DOI: 10.1084/jem.20210417
Authors: Johanna Strobl*, Laura Marie Gail*, Lisa Kleissl, Ram Vinay Pandey, Valerie Smejkal, Julian Huber, Viktoria Puxkandl, Ruth Dingelmaier-Hovorka, Denise Atzmüller, Thomas Krausgruber, Christoph Bock, Philipp Wohlfarth, Werner Rabitsch, Georg Stary;
Funding: The study was supported by funds of the Oesterreichische Nationalbank (Austrian Central Bank, Anniversary Fund, project number: 17872), by the Austrian Science Fund (FWF, P31494) and by the Innovation Fund of the Austrian Academy of Sciences (ÖAW, project number: IF_2017_29). JS was supported by a DOCmed fellowship of the Austrian Academy of Sciences.
Georg Stary is a fully trained dermatovenereologist with direct contact to patients and ample experience in research in organ-specific immunological processes. After a 4-year fellowship in the von Andrian Laboratory at Harvard Medical School, he became Senior Physician and Principal Investigator to the Department of Dermatology of the MedUni Vienna in 2014, where he was appointed Associate Professor in 2016. Since November 2018, he has been an Adjunct Principal Investigator at LBI-RUD and CeMM and has since been named Co-Director of LBI-RUD. His research projects focus on different aspects of host-pathogen interactions, the contribution of tissue-resident leukocytes to physiological and pathological immune responses and rare skin diseases.
The CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is an international, independent, and interdisciplinary research institution for molecular medicine under the scientific direction of Giulio Superti-Furga. CeMM is oriented towards medical needs and integrates basic research and clinical expertise to develop innovative diagnostic and therapeutic approaches for precision medicine. Research focuses on cancer, inflammation, metabolic and immune disorders, and rare diseases. The Institute's research building is located on the campus of the Medical University and the Vienna General Hospital. www.cemm.at
Medical University Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training center in the German-speaking countries. With 6,000 employees, 30 departments and two clinical institutes, 12 medical theory centers and numerous highly specialized laboratories, it is also one of Europe's leading research establishments in the biomedical sector.
The Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) was founded in April 2016 in a joint effort of Ludwig Boltzmann Gesellschaft, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, and St. Anna Children’s Cancer Research Institute. The three founding partner institutions, and CeRUD Vienna Center for Rare and Undiagnosed Diseases, constitute LBI-RUD’s most important collaboration partners. Research at LBI-RUD focuses on the deciphering of rare immunological, hematopoietic, nervous, dermal, gastro-intestinal, and hepatic diseases. Those studies provide unique insights into human biology and are the basis for the development of tailored therapeutic concepts in the sense of the personalized medicine of the future. The mission of LBI-RUD is – together with its partner institutions – to sustainably develop and maintain research infrastructure integrating scientific, societal, ethical, and economical aspects of rare diseases. www.rare-diseases.at
For further information please contact
Anna Maria Schwendinger
Head of PR & Communications
Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
Phone +43-1/40160-70 092
Fax +43-1/40160-970 000
aschwendingercemm [dot] oeaw [dot] ac [dot] at